PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Gadoquatrane→

Gadoquatrane PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not verified
Molecular formula
Not verified
Molecular weight
Not verified g/mol
Drug class
Gadolinium-based MRI contrast agenttetrameric macrocyclic non-ionic gadolinium chelate
Mechanism of action
The intact tetrameric macrocyclic gadolinium complex is paramagnetic and shortens T1 relaxation times, increasing signal intensity in tissues where the contrast agent distributes. It is a diagnostic contrast chelate, not a therapeutic agent.
Indications / reported uses
  • MRI contrast enhancement for adults and paediatric patients with known or suspected abnormalities of the central nervous system and other body regions under the applicable product authorisation; confirm current country-specific label and approval status before assigning precise indications

Sources: US DailyMed — Gadoquatrane product information · NLM MeSH — Gadoquatrane · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Gadoquatrane PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Gadoquatrane Permitted Daily Exposure (PDE) report (the Gadoquatrane PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Gadoquatrane Occupational Exposure Limit (OEL) report (the Gadoquatrane OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.